Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price1,766.90 INR
Fair value1,450.05
Ethical score30.0/100
RatingAVOID
Our investment reviews on this name
2026-10-02Read Distribution1,766.90+0.0% to today
2026-08-24Read Markdown1,706.00+3.6% to today
2026-07-16Read Accumulation1,706.00+3.6% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
SBI Life Insurance holds its Distribution at $1,766.90. Consolidating, no directional conviction, held for 495 days.
As held on the ledger · 2026-09-17
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 495 days
Price at the screen
$1,766.90
Valuation
71.91 trailing · 50.96 forward price to earnings
Values screen
FAIL· score 30.0
Beta
0.34
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Insurance — FAIL on business activity
Fail
Debt load
0.00%
Below 33%
Interest-bearing debt is 0.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.64%
Below 33%
Cash held in interest-bearing accounts and securities is 0.6% of assets, under the one-third limit.
Pass
Receivables
0.16%
Below 49%
Money owed to the company is 0.2% of assets, under the 49% limit.
Pass
Revenue purity
-0.01%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
SBI Life Insurance does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades above our $1,450.05 fair value estimate.
Fair value range in INR, drawn from the 2026-09-17 screen. The gold marker is the market price at the same screen. The price runs 17.9% above the base estimate.
Third-party analyst targets: 37 covering, consensus Strong Buy. The average target sits +35% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-17 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 51.0x forward earnings, the price already runs ahead of the business. It trades 18% above our $1,450.05 fair value, so you would be buying at a premium, not a discount.
The risks · The things to watch: its business and earnings are exposed to India and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SBILIFE.NS trades on NSE (the company is based in India). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347.
2026-07-23Accumulation$1,706.00+0.0%Entry 10
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-22Accumulation$1,706.00+0.0%Entry 9
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-21Accumulation$1,706.00+0.0%Entry 8
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20Accumulation$1,706.00+0.0%Entry 7
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19Accumulation$1,706.00+0.0%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Accumulation$1,706.00+0.0%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-17Accumulation$1,706.00+0.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-16Accumulation$1,706.00+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (37 analysts) rates it strong buy, with a mean price target of $2347. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The Ledger's Promise
This entry now belongs to the ledger. Whatever SBILIFE.NS does next, these words stay.
SBI Life Insurance · SBILIFE.NS · Distribution · $1,766.90
Recorded 2026-09-17 · before the outcome · scored mechanically